Damora Therapeutics (DMRA) Common Equity (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Common Equity came in at $511.6 million in Q1 2026, up 3631.88% YoY from $13.7 million in Q1 2025, and up 112.83% on a QoQ basis from $240.4 million in Q4 2025.
Damora Therapeutics (DMRA) Common Equity (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Common Equity data on file, last reported at $511.6 million in Q1 2026.
- Quarterly Common Equity rose 3631.88% year-over-year to $511.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $511.6 million (up 3631.88% YoY) and the FY2025 annual result came in at $240.4 million, up 1418.41% from the prior year.
- Common Equity rose to $511.6 million in Q1 2026, from $240.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $511.6 million in Q1 2026 to a low of $8.0 million in Q3 2025.
- A 5-year average of $79.9 million and a median of $37.4 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity sank 61.75% — and 2026, when it surged 3631.88%.
- Tracing DMRA's Common Equity over 5 years: stood at $61.8 million in 2022, then tumbled by 47.64% to $32.3 million in 2023, then plunged by 51.03% to $15.8 million in 2024, then jumped by 1418.41% to $240.4 million in 2025, then jumped by 112.83% to $511.6 million in 2026.
- The last three Common Equity figures came in at $511.6 million (Q1 2026), $240.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 516.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 516.06 Mn |
| Mar 31, 2026 | 511.60 Mn |
| Dec 31, 2025 | 240.38 Mn |
| Sep 30, 2025 | 8.01 Mn |
| Jun 30, 2025 | 10.95 Mn |
| Mar 31, 2025 | 13.71 Mn |
| Dec 31, 2024 | 15.83 Mn |
| Sep 30, 2024 | 20.94 Mn |
| Jun 30, 2024 | 23.59 Mn |
| Mar 31, 2024 | 28.16 Mn |
| Dec 31, 2023 | 32.33 Mn |
| Sep 30, 2023 | 37.38 Mn |
| Jun 30, 2023 | 43.70 Mn |
| Mar 31, 2023 | 50.33 Mn |
| Dec 31, 2022 | 61.75 Mn |
| Sep 30, 2022 | 72.73 Mn |
| Jun 30, 2022 | 85.07 Mn |
| Mar 31, 2022 | 101.31 Mn |
| Dec 31, 2021 | 117.22 Mn |
| Sep 30, 2021 | 129.62 Mn |